MSD grants UCL a royalty-free voluntary licence to make and sell generic alimatravir in 129 countries

A voluntary licence granted to an African manufacturer covering all 129 licensed countries, including every African country; African by licensee domicile and by licensed territory.


Coverage: The Meridian legal market record (editorial).

A voluntary licence granted to an African manufacturer covering all 129 licensed countries, including every African country; African by licensee domicile and by licensed territory.

Record ID TX-AFR-2026-0069
Record type Commercial IP transaction
Transaction type In-licensing, Non-exclusive licence, Technology transfer
IP rights patent, regulatory data, know-how
Status Signed
Qualifying date 2026-07-24
Sector Life sciences · HIV prevention (antiretrovirals)
African markets South Africa, Kenya, Nigeria, Egypt
Licensed territory 129 low- and lower-middle-income countries, including every African country.
Disclosed value Not disclosed in the sources reviewed.
Evidence Two or more independent secondary sources · 3 source(s)
Last verified 2026-10-25

Parties

  • Merck & Co. (MSD) (United States): licensor
  • UCL (Kenya): licensee, manufacturer

Key terms

  • Interest: non-exclusive royalty-free voluntary licence; Exclusivity: non-exclusive; Territorial scope: 129 low- and lower-middle-income countries including all of Africa; Term: Royalty-free; term not stated in the sources reviewed
  • Financial terms as reported: “royalty-free agreements”

Sources

  1. Aspen gets Merck licensing agreement to make lower-cost HIV pill, BusinessDay (Reuters), 2026-07-24
  2. Aspen signs voluntary HIV prevention pill licensing agreement with MSD, CNBC Africa, 2026-07-24
  3. AIDS 2026: some pieces falling into place for monthly HIV prevention pill, but key data not yet in, allAfrica, 2026-07-29

Part of The Meridian’s Africa IP database. Counts, market breakdowns and rankings are derived from published records only; a record counts once. Corrections: submit evidence.